Hi-Impacts

Company Overview

Snapshot

Founded in June 2012 by Eddy Papriov and Itzhak Fridman, Hi-Impacts operates with 1–10 employees. The company focuses on developing novel therapies using its proprietary Acoustic Pulse Technology (APT) device for medical applications.

Business overview

Hi-Impacts is a medical device company specializing in non-invasive, non-drug therapies for orthopedic, vascular, and urologic diseases. The company's core technology is a proprietary acoustic pulse technology (APT) device, designed for medical applications to treat inflammatory and ischemic conditions, and to facilitate fracture fusion. Hi-Impacts' patented APT device is compact and cost-effective, enabling treatments over large areas of the body. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Treatment & Therapeutics market with its B2B business model.

Company Intelligence Q&A

What is Hi-Impacts' primary focus?

Hi-Impacts is a medical device company dedicated to developing novel therapies that transform the standard of care for orthopedic, vascular, and urologic diseases through non-invasive, non-drug treatments.

What is the core technology developed by Hi-Impacts?

Hi-Impacts has developed a proprietary Acoustic Pulse Technology (APT) device, also known as shock wave technology, specifically engineered for various medical applications.

Which medical conditions does Hi-Impacts' APT device address?

The APT interventions developed by Hi-Impacts are primarily used to treat inflammatory and ischemic diseases, as well as to facilitate fracture fusion.

What are the key features of Hi-Impacts' patented APT device?

Hi-Impacts' patented APT device is characterized by its compact size, cost-effectiveness, and ability to treat large areas (50x350 mm), allowing for versatile application across the body in a short timeframe.

Who are the founders of Hi-Impacts?

Hi-Impacts was founded by Eddy Papriov, who serves as CEO, and Itzhak Fridman, who is the CSO.